Select the category that most closely reflects your concerns so we can review it and determine if it violates the Society Guidelines
DescriptionConclusions \n \nStatistically significant increases in age-adjusted mortality rates of all cancer and some specific types of cancer, namely, ovarian cancer, leukemia, prostate, lip/oral/pharyngeal, pancreatic, and breast cancers, were observed in 2022 after two-thirds of the Japanese population had received the third or later dose of SARS-CoV-2 mRNA-LNP vaccine. \n \nThese particularly marked increases in mortality rates of these ERα-sensitive cancers may be attributable to several mechanisms of the mRNA-LNP vaccination, \n \nrather than COVID-19 infection itself or reduced cancer care due to the lockdown. \n \nResearchers have reported that the SARS-CoV-2 mRNA-LNP vaccine may pose the risk of development and progression of cancer. \n \nSeveral case reports have described cancer developing or worsening after vaccination and discussed possible causal links between cancer and mRNA-LNP vaccination.
DescriptionConclusions \n \nStatistically significant increases in age-adjusted mortality rates of all cancer and some specific types of cancer, namely, ovarian cancer, leukemia, prostate, lip/oral/pharyngeal, pancreatic, and breast cancers, were observed in 2022 after two-thirds of the Japanese population had received the third or later dose of SARS-CoV-2 mRNA-LNP vaccine. \n \nThese particularly marked increases in mortality rates of these ERα-sensitive cancers may be attributable to several mechanisms of the mRNA-LNP vaccination, \n \nrather than COVID-19 infection itself or reduced cancer care due to the lockdown. \n \nResearchers have reported that the SARS-CoV-2 mRNA-LNP vaccine may pose the risk of development and progression of cancer. \n \nSeveral case reports have described cancer developing or worsening after vaccination and discussed possible causal links between cancer and mRNA-LNP vaccination.
